SCHEMBL6630360

SCHEMBL6630360

COc1ccc(CN2CCN(C(=O)O)CC2)cc1

nearest known ligand 0.69

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 1/20 0.69
POLB P06746 1/20 0.68
PKM P14618 1/20 0.68
FAAH O00519 1/20 0.67
ALDH1A1 P00352 2/20 0.64
LMNA P02545 1/20 0.62
HTT P42858 1/20 0.62
LSS P48449 1/20 0.60
SMN1; SMN2 Q16637 1/20 0.60
HRH3 Q9Y5N1 1/20 0.59
MEN1 O00255 2/20 0.59
KMT2A Q03164 2/20 0.59
KDM4E B2RXH2 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2232123 0.93 POLB (0.61) SIGMAR1POLBPKMFAAHALDH1A1
SCHEMBL13582238 0.92 HRH3 (0.73) SIGMAR1POLBPKMFAAHALDH1A1
SCHEMBL2232052 0.89 POLB (0.57) SIGMAR1POLBPKMFAAHALDH1A1
SCHEMBL2232206 0.89 POLB (0.57) SIGMAR1POLBPKMFAAHALDH1A1
SCHEMBL27856022 0.89 POLB (0.70) SIGMAR1POLBPKMFAAHALDH1A1
SCHEMBL19049377 0.88 HRH3 (0.71) SIGMAR1POLBPKMFAAHALDH1A1
SCHEMBL19002261 0.85 POLB (0.73) SIGMAR1POLBPKMFAAHALDH1A1
SCHEMBL19285228 0.85 SIGMAR1 (0.85) SIGMAR1POLBPKMALDH1A1LMNA
SCHEMBL1043952 0.85 SIGMAR1 (0.85) SIGMAR1POLBPKMALDH1A1LMNA
SCHEMBL20804352 0.85 SIGMAR1 (0.85) SIGMAR1POLBPKMALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2800565-B1 CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME LUNDBECK LA JOLLA RESEARCH CENTER INC (US) 2020-03-25 EP claimed
CN-1602191-A Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK AS (DK) 2005-03-30 CN claimed
EP-1458374-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-09-22 EP claimed
WO-2003051841-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 WO claimed
US-20240287094-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN MEDICINES JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) 2024-08-29 US disclosed
EP-4349836-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN MEDICINES Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) 2024-04-10 EP disclosed
CN-1326519-C Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK AS (DK) 2007-07-18 CN disclosed
CN-1602191-A Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK AS (DK) 2005-03-30 CN disclosed
US-4562189-A HYPOTENSIVE AGENTS AMERICAN CYANAMID COMPANY (US) 1985-12-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240287094-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN MEDICINES PARP1, PARP11, PARP8 SIGMAR1 4335/4885POLB 292/4885PKM 311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.